ENDRA Life Sciences (NDRA) shares more than doubled Tuesday after the company said a post market clinical study was started at the LMU University Hospital in Munich, Germany to assess the liver fat measurement capabilities of its TAEUS system.
The company said a first patient was scanned with the TAEUS system in the study, which is designed to assess the system's utility for managing metabolic disease.
ENDRA said it expects the collaboration with LMU researchers to augment clinical data and support the company's de novo submission to the US Food and Drug Administration by mid-2025.
Price: 0.49, Change: +0.27, Percent Change: +124.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。